| Catalog No. | HS856046 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Species | Human |
|---|
| Clonality | Monoclonal |
|---|
| Target | CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A |
|---|
| Endotoxin level | Please contact with the lab for this information. |
|---|
| Purity | >95% as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | Q16552 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
|---|
| Alternate Names | SHR-1314, 1792181-33-9 |
|---|
| Background | Ixekizumab is a humanized monoclonal antibody to interleukin-17A which acts as an antiinflammatory agent and is used to treat moderate-to-severe plaque psoriasis. Ixekizumab has not been linked to serum enzyme elevations during therapy or to instances of idiosyncratic acute liver injury.
• The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond., PMID:30127781
• Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability., PMID:26431948
• IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment., PMID:37579542
• The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases., PMID:34863654
• IL-17 for therapy., PMID:28633806
• Association Between., PMID:35271496
• Vunakizumab: First Approval., PMID:39497021
• The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies., PMID:31278139
• IL-17A Modulates Peritoneal Macrophage Recruitment and M2 Polarization in Endometriosis., PMID:32117261
• Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F., PMID:32973785
|
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
